Vinorelbine in Advanced BRAF-like Colon Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

March 17, 2020

Study Completion Date

March 17, 2020

Conditions
Colon Cancer
Interventions
DRUG

Vinorelbine Tartrate

Intravenous administration of vinorelbine on day 1 and day 8 in a dose of 30 mg/m2. One treatment cycle is 21 days.

Trial Locations (1)

1066 CX

Antoni van Leeuwenhoek, Amsterdam

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Vall d'Hebron Institute of Oncology

OTHER

collaborator

Agendia

INDUSTRY

collaborator

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

collaborator

Azienda Ospedaliera Niguarda Cà Granda

OTHER

collaborator

Fundación para la Investigación del Hospital Clínico de Valencia

OTHER

collaborator

University of Campania Luigi Vanvitelli

OTHER

collaborator

University of Turin, Italy

OTHER

collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Catalan Institute of Health

OTHER_GOV

collaborator

Universitaire Ziekenhuizen KU Leuven

OTHER

lead

The Netherlands Cancer Institute

OTHER

NCT03482362 - Vinorelbine in Advanced BRAF-like Colon Cancer | Biotech Hunter | Biotech Hunter